Program Description
Hyperglycemia is a common and clinically significant adverse effect associated with treatment with PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer. Hyperglycemia occurs because the PI3K/AKT pathway, which is targeted by these therapies to inhibit cancer cell growth, also plays a crucial role in normal glucose metabolism. This webinar will provide oncology pharmacists with a comprehensive overview of the PI3K/AKT/PTEN/mTOR pathway and its role in HR+ breast cancer, as well as the mechanism of action for the PI3K and AKT inhibitors. The pathophysiology of hyperglycemia induced by these agents will be the focus of the discussion, equipping oncology pharmacists with the knowledge to identify patients at risk and prepare for this common adverse effect. If not promptly identified and managed, hyperglycemia can lead to serious consequences, including dose interruptions or reductions that may compromise the effectiveness of the anti-cancer treatment for patients. The program will also review the incidence and severity of hyperglycemia as observed in pivotal clinical trials as well as in real-world settings.
Target audience: Oncology pharmacists, health system pharmacists, ambulatory care pharmacists
Type of activity: Application
Release date: October 14, 2025
Expiration date: December 15, 2025
Time to complete activity: 1.0 hour
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the mechanism of action, mutation targets, and clinical indications for FDA-approved PI3K and AKT inhibitors
- Explain the pathophysiologic mechanisms by which PI3K and AKT inhibitors cause hyperglycemia and how these differ from other drug-induced hyperglycemia mechanisms
- Analyze real-world and clinical trial data on the incidence of hyperglycemia in patients receiving PI3K and AKT inhibitors
